Cargando…
Comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials
BACKGROUND: Catecholamines, especially norepinephrine, are the most frequently used vasopressors for treating patients with septic shock. During the recent decades, terlipressin, vasopressin V1A agonist, and even Ca(2+) sensitizer were increasingly used by physicians. The aim of this study is to com...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518735/ https://www.ncbi.nlm.nih.gov/pubmed/31088524 http://dx.doi.org/10.1186/s13054-019-2427-4 |
_version_ | 1783418516939997184 |
---|---|
author | Cheng, Lu Yan, Jing Han, Shutang Chen, Qiuhua Chen, Mingqi Jiang, Hua Lu, Jun |
author_facet | Cheng, Lu Yan, Jing Han, Shutang Chen, Qiuhua Chen, Mingqi Jiang, Hua Lu, Jun |
author_sort | Cheng, Lu |
collection | PubMed |
description | BACKGROUND: Catecholamines, especially norepinephrine, are the most frequently used vasopressors for treating patients with septic shock. During the recent decades, terlipressin, vasopressin V1A agonist, and even Ca(2+) sensitizer were increasingly used by physicians. The aim of this study is to compare the efficacy of such different kinds of vasoactive medications on mortality among patients with septic shock. METHODS: Relevant randomized controlled trials were identified by searching PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials updated to February 22, 2018. A network meta-analysis was performed to evaluate the effect of different types of vasoactive medications. The primary outcome was 28-day mortality. Intensive care unit (ICU) mortality, hospital and ICU length of stay (LOS), and adverse events were also assessed. RESULTS: A total of 43 trials with 5767 patients assessing 17 treatment modalities were included. Treatments ranking based on surface under the cumulative ranking curve values from largest to smallest were NE/DB 85.9%, TP 75.1%, NE/EP 74.6%, PI 74.1%, EP 72.5%, VP 66.1%, NE 59.8%, PE 53.0%, DA 42.1%, DX 38.2%, SP 27.0%, PA 24.3%, EX 22.8%, LE 21.5%, and DB 13.3% for 28-day mortality. Treatments ranking for ICU mortality were TP/NE 86.4%, TP 80.3%, TP/DB/NE 65.7%, VP/NE 62.8%, NE 57.4%, VP 56.5%, PE 48.4%, DA 33.0%, PA 27.5%, LE 22.1%, and DB 9.9%. The incidence of myocardial infarction was reported with NE/EP 3.33% (n = 1 of 30), followed by EP 3.11% (n = 5 of 161), and then VP 3.10% (n = 19 of 613), NE 3.03% (n = 43 of 1417), DA 2.21% (n = 19 of 858), NE/DB 2.01% (n = 4 of 199), LE 1.16% (n = 3 of 258), and PA 0.39% (n = 1 of 257). The incidence of arrhythmia was reported with DA 26.01% (n = 258 of 992), followed by EP 22.98% (n = 37 of 161), and then NE/DB 20.60% (n = 41 of 199), NE/EP 20.0% (n = 6 of 30), NE 8.33% (n = 127 of 1525), LE 5.81% (n = 15 of 258), PA 2.33% (n = 6 of 257), and VP 1.67% (n = 10 of 600). CONCLUSIONS: The use of norepinephrine plus dobutamine was associated with lower 28-day mortality for septic shock, especially among patients with lower cardiac output. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13054-019-2427-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6518735 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-65187352019-05-21 Comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials Cheng, Lu Yan, Jing Han, Shutang Chen, Qiuhua Chen, Mingqi Jiang, Hua Lu, Jun Crit Care Research BACKGROUND: Catecholamines, especially norepinephrine, are the most frequently used vasopressors for treating patients with septic shock. During the recent decades, terlipressin, vasopressin V1A agonist, and even Ca(2+) sensitizer were increasingly used by physicians. The aim of this study is to compare the efficacy of such different kinds of vasoactive medications on mortality among patients with septic shock. METHODS: Relevant randomized controlled trials were identified by searching PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials updated to February 22, 2018. A network meta-analysis was performed to evaluate the effect of different types of vasoactive medications. The primary outcome was 28-day mortality. Intensive care unit (ICU) mortality, hospital and ICU length of stay (LOS), and adverse events were also assessed. RESULTS: A total of 43 trials with 5767 patients assessing 17 treatment modalities were included. Treatments ranking based on surface under the cumulative ranking curve values from largest to smallest were NE/DB 85.9%, TP 75.1%, NE/EP 74.6%, PI 74.1%, EP 72.5%, VP 66.1%, NE 59.8%, PE 53.0%, DA 42.1%, DX 38.2%, SP 27.0%, PA 24.3%, EX 22.8%, LE 21.5%, and DB 13.3% for 28-day mortality. Treatments ranking for ICU mortality were TP/NE 86.4%, TP 80.3%, TP/DB/NE 65.7%, VP/NE 62.8%, NE 57.4%, VP 56.5%, PE 48.4%, DA 33.0%, PA 27.5%, LE 22.1%, and DB 9.9%. The incidence of myocardial infarction was reported with NE/EP 3.33% (n = 1 of 30), followed by EP 3.11% (n = 5 of 161), and then VP 3.10% (n = 19 of 613), NE 3.03% (n = 43 of 1417), DA 2.21% (n = 19 of 858), NE/DB 2.01% (n = 4 of 199), LE 1.16% (n = 3 of 258), and PA 0.39% (n = 1 of 257). The incidence of arrhythmia was reported with DA 26.01% (n = 258 of 992), followed by EP 22.98% (n = 37 of 161), and then NE/DB 20.60% (n = 41 of 199), NE/EP 20.0% (n = 6 of 30), NE 8.33% (n = 127 of 1525), LE 5.81% (n = 15 of 258), PA 2.33% (n = 6 of 257), and VP 1.67% (n = 10 of 600). CONCLUSIONS: The use of norepinephrine plus dobutamine was associated with lower 28-day mortality for septic shock, especially among patients with lower cardiac output. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13054-019-2427-4) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-14 /pmc/articles/PMC6518735/ /pubmed/31088524 http://dx.doi.org/10.1186/s13054-019-2427-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Cheng, Lu Yan, Jing Han, Shutang Chen, Qiuhua Chen, Mingqi Jiang, Hua Lu, Jun Comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials |
title | Comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials |
title_full | Comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials |
title_fullStr | Comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials |
title_full_unstemmed | Comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials |
title_short | Comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials |
title_sort | comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518735/ https://www.ncbi.nlm.nih.gov/pubmed/31088524 http://dx.doi.org/10.1186/s13054-019-2427-4 |
work_keys_str_mv | AT chenglu comparativeefficacyofvasoactivemedicationsinpatientswithsepticshockanetworkmetaanalysisofrandomizedcontrolledtrials AT yanjing comparativeefficacyofvasoactivemedicationsinpatientswithsepticshockanetworkmetaanalysisofrandomizedcontrolledtrials AT hanshutang comparativeefficacyofvasoactivemedicationsinpatientswithsepticshockanetworkmetaanalysisofrandomizedcontrolledtrials AT chenqiuhua comparativeefficacyofvasoactivemedicationsinpatientswithsepticshockanetworkmetaanalysisofrandomizedcontrolledtrials AT chenmingqi comparativeefficacyofvasoactivemedicationsinpatientswithsepticshockanetworkmetaanalysisofrandomizedcontrolledtrials AT jianghua comparativeefficacyofvasoactivemedicationsinpatientswithsepticshockanetworkmetaanalysisofrandomizedcontrolledtrials AT lujun comparativeefficacyofvasoactivemedicationsinpatientswithsepticshockanetworkmetaanalysisofrandomizedcontrolledtrials |